Question 2 (3 points) To test the effectiveness of monoclonal antibodies in preventing the development of severe disease in 1,035 patients with mild to moderate COVID-19, researchers randomly assigned 518 to receive the monoclonal antibody product and 517 to receive the placebo. Neither the patients nor the doctors who evaluated them knew who was in which group. Only 2% of the treatment group required hospitalization or died, compared to 7% of the placebo group. The results were highly statistically significant (p